ArsenalBio to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
ArsenalBio, a privately held programmable cell therapy company focused on building advanced CAR T therapies for solid tumors, today announced that members of its senior management team are scheduled to participate in the Morgan Stanley 19th Annual Global Healthcare Conference on Friday, September 10, 2021 at 12:30 p.m. ET. The presentation will feature a business overview and update by Ken Drazan, MD, ArsenalBio's Chairman and Chief Executive Officer.
A live webcast of the event will be available here. A replay of the webcast will be available at the same location for 90 days following the presentation.
About ArsenalBio
ArsenalBio is a privately held, programmable cell therapy company focused on the realization of solid tumor cell therapy by helping more patients fight cancer and saving lives. Its discovery engine comprises precise genome editing using CRISPR-enabled CITE, integrated circuits incorporating its PrimeRtm logic gates and therapeutic enhancements from its CARchitecturetm library, enabling multiple pharmaceutical functions. With our programmable and computationally driven approach, we aim for enhanced and broader efficacy, increased patient safety, reduced provider costs and expanded market access. To learn more, visit www.arsenalbio.com and follow us on Twitter @ArsenalBio, LinkedIn and Facebook.
The Board of Directors of Revvity , today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 9, 2024 to all shareholders of record at the close of business on July 19, 2024.
About Revvity ...
Edwards Lifesciences today reported financial results for the quarter ended March 31, 2024.
Highlights and Outlook
Q1 sales grew 10% on a reported and constant currency1 basis to $1.6 billion
Q1 TAVR sales grew 6%; constant currency sales...
A functional assessment of Bacillus subtilis PLSSC (SEBtilistm) demonstrated its antimicrobial activity and capability to offer health benefits through industrial processing and the digestion process, showing its value-add in functional foods,...
Cronos Group Inc. ("Cronos" or the "Company") will hold its 2024 first quarter earnings conference call on Thursday, May 9, 2024 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for...
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today...
Stevanato Group S.p.A. , a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first...
